First US Lucentis Biosimilar Expected By Year End, Roche Confirms
Samsung Bioepis’ SB11 Biosimilar Pending With FDA
Another of Roche’s biologic blockbusters is due to bite the dust this year, the originator has confirmed, with biosimilar competition to Lucentis forecast in the second half of 2021.
You may also be interested in...
The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.
Samsung Bioepis’ indication that it will not launch its FDA-approved ranibizumab biosimilar, Byooviz, before June 2022 has changed what we know about the competitive landscape for Lucentis in the US.
Regeneron Pharmaceuticals has spoken out on the implication of impending competition to Lucentis for its rival product Eylea, as the market for biosimilar Lucentis looks to form by the close of this year.